Voyager Acquisition Corp., a Cayman Islands SPAC, disclosed in its May 20, 2026 10-Q filing significant amendments to its business combination and sponsor support agreements with Veraxa Biotech AG, reflecting active deal structuring ahead of closing. Shareholder redemptions remain a material factor, with approximately $885,556 left in trust after over 25 million shares were redeemed. The company’s cash position is minimal, emphasizing dependence on transaction completion and warrant exercises to secure financing. The combined entity targets growth from Veraxa’s innovative oncology pipeline, though transaction risks and regulatory hurdles remain key watchpoints.